Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
ZUSDURI (MITOMYCIN) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
ZUSDURI
NDA
Get alerts
MITOMYCIN | N215793 | UROGEN PHARMA LTD
1 strength
4 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
DMF
Approvals
Label
Products
Patent Timeline
4 unique patents, 1 exclusivity by expiration date
Active (4)
Today
Exclusivity
2027
2028
2029
2030
2031
Today
9040074
Jan. 20, 2031
9950069
Jan. 20, 2031
10039832
Jan. 20, 2031
12440568
Jan. 20, 2031
NP
Jun. 12, 2028
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 40MG/VIAL
RLD
4 patents
1 exclusivity
▴
POWDER;INTRAVESICAL | Approved: Jun 12, 2025
Patents (4)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
9040074
Jan 20, 2031
—
—
Yes
U-4256
TREATMENT OF ADULT PATIENTS WITH RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER
—
9950069
Jan 20, 2031
—
—
Yes
U-4256
TREATMENT OF ADULT PATIENTS WITH RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER
—
10039832
Jan 20, 2031
—
—
—
U-4256
TREATMENT OF ADULT PATIENTS WITH RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER
—
12440568
Jan 20, 2031
—
—
—
U-4256
TREATMENT OF ADULT PATIENTS WITH RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER
—
Exclusivities (1)
Code
Date
Status
NP
Jun 12, 2028
Active